


# UK NEQAS


International Quality Expertise



## 2023-2024

# Services Available List

EQA programme directory for all UK NEQAS Centres



[www.ukneqas.org.uk](http://www.ukneqas.org.uk)



# Who are UK NEQAS?

United Kingdom National External Quality Assessment Service (UK NEQAS) is the **world leading** provider of clinical laboratory External Quality Assessment (EQA)/Proficiency Testing (PT) programmes. The EQA/PT programmes provided by UK NEQAS are designed and operated by highly experienced organisers and scientists, wholly committed to improving the quality of testing in healthcare laboratories for the benefit of patients worldwide.

To ensure the provision of high quality EQA/PT and delivery of appropriate scientific support in each specialist area of clinical laboratory testing, each UK NEQAS service is operated from a dedicated expert centre. These 20 centres are in 11 cities around the UK and together they form the UK NEQAS Consortium, a not-for-profit company limited by guarantee and a UK Registered Charity (no: 1044013). Each UK NEQAS member centre operates on a strict not for profit basis, has no commercial interests and is **accredited to ISO 17043:2010**.

***“The EQA/PT programmes provided by UK NEQAS are designed and operated by highly experienced organisers and scientists”***

In addition to delivering over 500 different EQA/PT programmes, UK NEQAS also operates PrepQ, a dedicated Pre- and Post- Analytical Quality Monitoring service which has been designed to allow participating laboratories to monitor their pre and post analytical issues to support the requirements of ISO 15189.

To supplement the UK NEQAS EQA/PT programmes and ensure that any findings identifying factors associated with good or poor performance are shared with laboratories, we regularly publish in peer reviewed journals, host scientific meetings and run educational webinars.

At UK NEQAS we believe that this approach ensures the best possible quality service is provided to clinical laboratories, and that this supports the continual improvement of healthcare service delivery worldwide. When selecting an EQA/PT service, it is clear to see why thousands of laboratories globally have chosen to use UK NEQAS.

Thank you for selecting and supporting UK NEQAS.

Liam Whitby  
President, UK NEQAS

## Our Mission

IMPROVING GLOBAL  
DIAGNOSTIC TESTING FOR  
THE BENEFIT OF PATIENTS THROUGH  
QUALITY ASSESSMENT AND EDUCATION

# Contents

## Cellular Pathology

**Pages 4-5**

Cellular Pathology Technique

Head & Neck Pathology

Immunocytochemistry & In-Situ Hybridisation

## Clinical Chemistry

**Pages 5-6**

Birmingham Quality

Cardiac Markers

Edinburgh Peptide Hormones

Guildford Peptide Hormones & Trace Elements

## Genomics

**Pages 7-9**

GenQA

## Haematology

**Pages 9-12**

Blood Coagulation

Blood Transfusion Laboratory Practice

Haematology

Leucocyte Immunophenotyping

## Immunology

**Pages 12-13**

Histocompatibility & Immunogenetics

Immunology, Immunochemistry & Allergy

## Medical Microbiology

**Page 13-14**

Microbiology

Parasitology

## Reproductive Science

**Page 15**

Reproductive Science

## Point of Care Testing

**Page 16**

## PrepQ

**Page 17**

## Participating Countries

**Pages 18-19**


## Programme Index

**Pages 20-28**


## UK NEQAS Centre Contacts

**Back page**

# Cellular Pathology

Cellular Pathology Technique	
<b>Tel:</b>	+44 (0) 191 816 1030
<b>Website:</b>	www.ukneqascpt.org.uk 
<b>Email:</b>	cpt@ukneqas.org.uk
<b>Legal Entity:</b>	LabXCell LTD
Services Available	
Slide Based Schemes	
Tissue Diagnostics	
Specialist Techniques	
Neuropathology	
Frozen Section (Companion Scheme to Specialist Techniques and Neuropathology)	
Mega Block (Companion Scheme to Specialist Techniques and Neuropathology)	
Muscle Histochemistry	
Renal Biopsy Pathology	
Diagnostic Cytopathology	
Diagnostic Cytopathology Cell Block	
Bone Marrow Trepine Biopsy (BMT)	
Mohs' Procedure	
Web Based Schemes	
Transmission Electron Microscopy (TEM)	
Direct Immunofluorescence (DIF)	
Digital Pathology (Pilot)	
Digital Interpretive Web Based Schemes	
Digital Interpretative Diagnostic Cytopathology	
Digital Diagnostic Ultrastructural Pathology (Pilot)	
Digital Interpretative Synovial Fluid	

Head & Neck Pathology	
<b>Tel:</b>	+44 (0) 121 371 5723
<b>Email:</b>	neckpath@ukneqas.org.uk
<b>Legal Entity:</b>	British Society for Oral & Maxillofacial
Services Available	
Head and Neck Pathology (Oral, ENT &	

Immunocytochemistry & In-Situ Hybridisation	
<b>Tel:</b>	+44 (0) 208 187 9174
<b>Website:</b>	www.ukneqasiccish.org 
<b>Email:</b>	info@ukneqasiccish.org
<b>Legal Entity:</b>	External Quality Assessment Services for Cancer Diagnostics CIC
Services Available	
Immunocytochemistry	
Alimentary Tract Pathology (GIST)	
Breast Pathology (HER2 IHC)	
Breast Pathology (Low Expression HER2 IHC) (Pilot)	
Breast Pathology (Hormonal Receptors ER & PR)	
Breast Pathology (Hormonal Receptors ER only)	
Cytopathology	
Gastric HER2 IHC	
General Pathology	
Lymphoid Pathology	
Mismatch Repair (MMR) Proteins	
Neuropathology	
Non-Small Cell Lung Cancer (NSCLC) ALK IHC	
Non-Small Cell Lung Cancer (NSCLC) PD-L1 IHC (Pilot)	

# Cellular Pathology

Immunocytochemistry & In-Situ Hybridisation	
Services Available	
<b>Immunocytochemistry (cont.)</b>	
Non-Small Cell Lung Cancer (NSCLC) ROS1 IHC (Pilot)	
Triple Negative Breast Cancer (TNBC) PD-L1 IHC (Pilot)	
Ki-67 in Breast Cancer (Pilot)	
p16 in Head & Neck Pathology (Pilot)	
<b>In-Situ Hybridisation</b>	
Breast HER2 ISH (Interpretive and Technical)	
Non-Small Cell Lung Cancer (NSCLC) ALK ISH (Pilot)	
Non-Small Cell Lung Cancer (NSCLC) ROS1 FISH (Pilot)	
High-risk HPV in Head & Neck Pathology (Pilot)	


# Clinical Chemistry


Birmingham Quality	
<b>Tel:</b>	+44 (0) 121 414 7300
<b>Website:</b>	www.birminghamquality.org.uk 
<b>Email:</b>	birminghamquality@uhb.nhs.uk
<b>Legal Entity:</b>	University Hospitals Birmingham NHS Foundation Trust
Services Available	
ACE	
Acute and Chronic Kidney Disease (Creatinine, Cystatin C, eGFR and AKI)	
Antibiotic Assays	
Antifungal Assays	
Bile Acids	
Clinical Chemistry	
Erythropoietin	
Faecal Haemoglobin	

# Clinical Chemistry


Birmingham Quality
Services Available
Faecal Markers
Faecal Pancreatic Elastase
Fluids
Fructosamine
Glycated Haemoglobins
Haematinics
Holo-transcobalamin
Immunosuppressants
Interpretative Comments in Clinical Chemistry
Intrinsic Factor Antibodies
Lipid Investigations
Newborn Screening
Paediatric Bilirubin
Plasma Metanephrines
Quantitative Amino Acids
Serum Indices (HIL)
Specific Proteins
Steroid Hormones
Sweat Testing
Thyroglobulin
Thyroid Hormones
Toxicology (TOX) and Therapeutic Drug Monitoring (TDM)
Urinary Catecholamines & Metabolites
Urine Chemistries
Urine Dipsticks
Vitamin Assays (Carotene, Vitamin A & E)
Vitamin D
Vitamin K

# Clinical Chemistry

Cardiac Markers	
<b>Tel:</b>	+44 (0) 141 440 2888
<b>Website:</b>	www.ukneqas-cm.org.uk 
<b>Email:</b>	info@ukneqas-cm.org.uk
<b>Legal Entity:</b>	NHS Greater Glasgow & Clyde
Services Available	
Cardiac Markers Schemes (Laboratory)	
hs Cardiac Troponin I, hs Cardiac Troponin T, CKMB, Myoglobin, NT-proBNP	
B-Type Natriuretic Peptide (BNP)	
Cardiac Markers Schemes (Point of Care)	
Cardiac Troponin I, Cardiac Troponin T, CKMB, Myoglobin, NT-proBNP	
High Sensitivity Cardiac Troponin I (Pilot)	


Edinburgh Peptide Hormones	
<b>Tel:</b>	+44 (0) 131 242 6885
<b>Website:</b>	www.edqas.org 
<b>Email:</b>	ukneqas@ed.ac.uk
<b>Legal Entity:</b>	NHS Lothian
Services Available	
Maternal Serum Screening	
1st Trimester (Down's syndrome and Trisomies T13 and T18)	
1st Trimester (Down's syndrome using dried blood spots) (Pilot)	
2nd Trimester (Down's syndrome)	
2nd Trimester (Neural tube defects)	
Pre-eclampsia Markers	
Placental Growth Factor (PLGF)	
sFlt-1	
sFlt-1: PLGF ratio	
Peptide I	
FSH, LH, AMH, Prolactin and Growth Hormone	

Edinburgh Peptide Hormones	
Services Available	
Peptide II	
PTH, ACTH and Calcitonin	
Tumour Markers	
AFP, CEA and hCG	
Pregnancy Testing	
Urinary hCG (Qualitative and Quantitative)	
Liver Fibrosis Markers	
Type III Procollagen Peptide (PIIINP)	
Enhanced Liver Fibrosis (ELF) Score	
FIB-4 Score	
Hyaluronic acid	
Tissue inhibitor of metalloproteinase I (TIMP-I)	

Guildford Peptide Hormones & Trace Elements	
<b>Tel:</b>	+44 (0) 148 357 1122 ext. 3611
<b>Website:</b>	www.surreyeqas.org.uk 
<b>Email:</b>	rsch.peptideeqa@nhs.net rsc-tr.Guildford-EQA@nhs.net
<b>Legal Entity:</b>	Frimley Health NHS Foundation Trust
Services Available	
C-Peptide	
Gastrin	
Insulin	
Insulin-like Growth Factor 1	
Insulin-like Growth Factor Binding Protein-3	
Lead, Cadmium, Manganese, Arsenic, Magnesium*, Mercury, Zinc*, Selenium, Thallium, Chromium and Cobalt in Whole Blood	
Mercury, Cadmium, Copper, Iron, Zinc, Chromium, Cobalt, Arsenic, Lead, Manganese, Nickel, Thallium and Selenium in Urine	
Zinc, Copper, Aluminium, Selenium, Chromium and Cobalt in Serum	

\* not included in the current scope of accreditation

# Genomics

Genomics (GenQA)	
<b>Tel:</b>	+44 (0) 131 242 6898
<b>Website:</b>	www.genqa.org 
<b>Email:</b>	info@genqa.org
<b>Legal Entity:</b>	Oxford University Hospitals NHS Foundation Trust
Services Available	
Clinical Genetics & Genetic Counselling	
Clinical Genetics - Cardiovascular disorders	
Clinical Genetics - Dysmorphology	
Clinical Genetics - Metabolic disorders	
Clinical Genetics - Monogenic disorders	
Clinical Genetics - Oncogenetic disorders	
Genetic counselling	
Genomic multi-disciplinary team (MDT) working	
Genomic and Inherited Disorders	
Ataxia, including Hereditary Spastic Paraplegia (HSP)	
Calcium disorders	
Cardiac disorders	
Charcot Marie Tooth disease and related sensory and motor neuropathies	
Chromosome Instability syndromes	
Cystic fibrosis and <i>CFTR</i> -related disorders	
Developmental delay	
Differences in sex development	
Epilepsy disorders	
Eye disorders	
Familial colorectal cancer and polyposis	
Familial endocrine tumour predisposition disorders	
Familial Hypercholesterolaemia	
Fragile X syndrome and <i>FMR1</i> -related disorders	
Gastrohepatology disorders	

Genomics (GenQA)	
Services Available	
Genomic and Inherited Disorders (cont.)	
Hereditary breast and ovarian cancer disorders (HBOC)	
Huntington disease and DRPLA	
Hypotonic Infant	
Imprinting disorders	
Inborn errors of metabolism	
Infertility	
Linkage analysis	
Microdeletion syndromes	
Mitochondrial disease	
Muscular dystrophies	
Neurodegenerative disorders	
Neurofibromatosis and rasopathies	
Postnatal constitutional copy number variants (CNV) detection	
Postnatal karyotyping	
Primary Immunodeficiency disorders (PID)	
Renal disorders	
Respiratory disorders	
Skeletal Dysplasias	
X-inactivation	
Haematological Neoplasms	
Acute Lymphoblastic Leukaemia (ALL)	
Chronic Lymphocytic Leukaemia (CLL)	
Chronic Lymphocytic Leukaemia (CLL) IGHV mutation status	
Chronic Lymphocytic Leukaemia (CLL) <i>TP53</i> analysis	
Haematological Technical FISH	
Lymphoma	
Lymphoma Technical NGS	
Myeloid disorders	
Myeloma	

\*Not within the current scope of accreditation

<sup>2</sup> Provided in collaboration with UKNEQAS LI

<sup>1</sup> Provided in collaboration with EMQN

<sup>3</sup> Provided in collaboration with UK NEQAS Microbiology

# Genomics

Genomics (GenQA)
Services Available
<b>Individual Competency Assessment</b>
Classification of <i>BRCA1</i> , <i>BRCA2</i> and other <i>HRR</i> gene variants
Classification of germline variants (SNVs and CNVs)
Genomic laboratory training videos
Tissue assessment
<b>Molecular Newborn Screening</b>
Molecular testing for cystic fibrosis (CF)
Molecular testing for Medium-chain acyl-CoA dehydrogenase deficiency (MCADD)
Molecular testing for Severe Combined Immunodeficiency (SCID)
Molecular testing for Spinal Muscular Atrophy (SMA)
<b>Molecular Pathology</b>
BRCA testing for ovarian and prostate cancer - somatic
BRCA testing for ovarian, breast, prostate and pancreatic cancer - germline
BRCA testing in prostate cancer – cfDNA
Breast cancer - <i>PIK3CA</i> testing
Breast cancer - Tumour expression profiling
Central Nervous System (CNS) tumours
Cholangiocarcinoma
Colorectal cancer - core
Colorectal cancer - MMR
Endometrial tumours
Gastrointestinal Stromal Tumours (GIST)
Lung cancer - Circulating free (cf) DNA in lung cancer
Lung cancer – comprehensive molecular
Lung cancer - EGFR
Lung cancer – fusions FISH/IHC
Lung cancer – fusions molecular
Melanoma
Microsatellite Instability (MSI)

Genomics (GenQA)
Services Available
<b>Molecular Pathology (cont.)</b>
Molecular Tissue identification
NTRK fusions
Renal tumours
Sarcoma
Thyroid cancer
<b>Pharmacogenomics</b>
Aminoglycoside Induced deafness
Pharmacogenomics panel
Prediction of Clopidogrel effectiveness ( <i>CYP2C19</i> )
Prediction of Fluorouracil toxicity ( <i>DPYD</i> )
Prediction of Thiopurine toxicity ( <i>TPMT</i> & <i>NUDT15</i> )
<b>Preimplantation Genetic Testing (PGT)</b>
PGT for aneuploidies (PGT-A)
PGT for blastomere FISH
PGT for monogenic disorders
PGT for structural rearrangements (PGT-SR)
<b>Reproductive Genetics</b>
Abnormal ultrasound
Carrier screening
Maternal cell contamination (MCC) and fetal sexing
Non-invasive prenatal testing (NIPT) for common aneuploidies
Non-invasive prenatal testing (NIPT) for common microdeletions
Non-invasive prenatal testing (NIPT) for fetal RhD status
Non-invasive prenatal testing (NIPT) for fetal sexing
Pregnancy loss
Prenatal constitutional copy number variant (CNV) detection
Prenatal karyotyping

\*Not within the current scope of accreditation

<sup>2</sup> Provided in collaboration with UKNEQAS LI


<sup>1</sup> Provided in collaboration with EMQN

<sup>3</sup> Provided in collaboration with UK NEQAS Microbiology

# Genomics

# Haematology

Genomics (GenQA)
<b>Services Available</b>
<b>Reproductive Genetics (cont.)</b>
Rapid prenatal testing for common aneuploidies
<b>Sample Handling</b>
DNA extraction from formalin-fixed paraffin embedded (FFPE) tissue
DNA extraction from fresh tissue
DNA extraction from saliva
DNA extraction from venous blood
DNA quantification
<b>Technical</b>
Next Generation Sequencing (NGS) for germline CNVs
Next Generation Sequencing (NGS) for germline SNVs and indels
Next Generation Sequencing (NGS) for somatic SNVs and indels - tumour testing only
Next Generation Sequencing (NGS) for somatic SNVs and indels - tumour with germline subtraction analysis
Optical Genome Mapping
<b>Variant Classification &amp; Interpretation</b>
Classification of germline SNVs and indels
Classification and interpretation of germline SNVs and indels
Exome trio sequencing - postnatal
Exome trio sequencing - prenatal
ISCN
Pathogenicity of germline postnatal copy number variants (CNV)
Pathogenicity of haematological neoplasm variants
Pathogenicity of prenatal copy number variants (CNV)
Pathogenicity of RNA splicing variants
Pathogenicity of somatic sequence variants
Variant validation

Blood Coagulation	
<b>Tel:</b>	+44 (0) 114 267 3300
<b>Website:</b>	www.ukneqasbc.org 
<b>Email:</b>	<a href="mailto:neqas@coageqa.org.uk">neqas@coageqa.org.uk</a>
<b>Legal Entity:</b>	Sheffield Teaching Hospitals NHS Foundation Trust
Services Available	
Screening Tests	
Prothrombin Time (PT)/INR (Venous/Capillary Methods)	
Prothrombin Time for Diagnosis (PT/Diagnostic) (PTD)	
Activated Partial Thromboplastin Time (APTT)	
Heparin Dosage Assessment (HDA) by APT	
Heparin Assay (HA) - Anti-Xa	
Thrombin Time (TT)	
Fibrinogen Assay (Clauss/MultifibrinU)	
D-Dimer	
Assays	
Factor II, V, VII VIII, IX, X, XI, XII Assays	
Von Willebrand Factor Antigen: Assay	
VWF:CB (Collagen-Binding) Assay	
VWF:RCo (Activity) Assay	
Antithrombin Antigen and Activity Assays	
Protein C Antigen and Activity Assay	
Protein S Total and Free Antigen Assay	
Protein S Activity Assay	
Activated Protein C Resistance Assay	
Plasminogen Assay	
Other Programmes	
ADAMTS13 Assays	
DOAC Assays (Dabigatran, Rivaroxaban, Apixaban, Edoxaban)	
Lupus Anticoagulant Screening/Assay	
FXIII Assays	
Homocysteine Assays	

\*Not within the current scope of accreditation


<sup>2</sup> Provided in collaboration with UKNEQAS LI

<sup>1</sup> Provided in collaboration with EMQN


<sup>3</sup> Provided in collaboration with UK NEQAS Microbiology

# Haematology

Blood Coagulation	
Services Available	
<b>Other Programmes (cont.)</b>	
FVIII Treatment Monitoring	
FIX Treatment Monitoring*	
Factor VIII Inhibitor Assay*	
Emicizumab Assays*	
HIT Screening/Assays*	
Molecular Genetics of Thrombophilia Testing (Factor V Leiden)	
Genetics of Heritable Bleeding and Thrombotic Disorders	
<b>Point of Care Testing (POCT)</b>	
Activated Clotting Time (ACT) for: Hemochron series ACT+, ACT-LR; i – Stat1, i – Stat Alinity	
INR for: CoaguChek XS, CoaguChek XS Plus, CoaguChek XS Pro & Pro II, Xprecia Stride, istat, LumiraDx	
D-Dimer for: Triage, Cobas H232	
Thromboelastometry for: Rotem Delta, Rotem Sigma	
Thromboelastography for: TEG & TEG6	

Blood Transfusion Laboratory Practice (BTLP)	
<b>Tel:</b>	+44 (0) 192 358 7111
<b>Website:</b>	<a href="http://www.ukneqasbtlp.org">www.ukneqasbtlp.org</a> 
<b>Email:</b>	<a href="mailto:btlp@ukneqas.org.uk">btlp@ukneqas.org.uk</a>
<b>Legal Entity:</b>	West Hertfordshire Teaching Hospitals NHS Trust
Services Available	
<b>ABO Titration (ABOT)</b>	
ABO Titration	
A <sub>1</sub> Typing	
<b>Direct Antiglobulin Testing (DAT)</b>	
Detection of Cells Coated with IgG	
Detection of Cells Coated with C3d	


Blood Transfusion Laboratory Practice (BTLP)	
Services Available	
<b>Fetomaternal Haemorrhage (FMH)</b>	
FMH Screening	
FMH Quantification	
<b>Point of Care D Typing (POCTD)</b>	
RhD Typing	
<b>Pre-Transfusion Testing (PTT)</b>	
ABO & D Grouping	
Antibody Screening	
Antibody Identification	
Crossmatching	
Rh and K Phenotyping	
<b>Antenatal Antibody Titration (ANT) (Pilot)</b>	
Red Cell Antibody Titration	
<b>Extended Red Cell Phenotyping (ERP) (Pilot)</b>	
Various Blood Group Antigen Phenotyping	
<b>Red Cell Genotyping (RCG) (Pilot)</b>	
Genotyping and Predicted Red Cell Phenotype for Various Blood Groups	
<b>Educational</b>	
Training, Assessment and Competency Tool (TACT)	

Haematology	
<b>Tel:</b>	+44 (0) 192 358 7111
<b>Website:</b>	<a href="http://www.ukneqas.org">www.ukneqas.org</a> 
<b>Email:</b>	<a href="mailto:haem@ukneqas.org">haem@ukneqas.org</a>
<b>Legal Entity:</b>	West Hertfordshire Teaching Hospitals NHS Trust
Services Available	
<b>Automated Counting &amp; Related</b>	
Automated Differential Leucocyte Count	
Blood Component Quality Monitoring	
Erythrocyte Sedimentation Rate	
Full Blood Count	

\* not included in the current scope of accreditation

# Haematology

Haematology
<b>Services Available</b>
<b>Automated Counting &amp; Related (cont.)</b>
Haemoglobin only
Infectious Mononucleosis
Plasma Viscosity
POCT Haematology (Pilot)
Reticulocyte Count
Reticulocyte Haemoglobin Content (Pilot)
<b>Haemoglobinopathies and Thalassaemia</b>
Abnormal Haemoglobins
DNA Diagnostics for Haemoglobinopathies
Liquid Newborn Haemoglobinopathy Screening
Newborn Sickle Screening
Sickle Screening only
<b>Morphology Related</b>
Blood Films for Morphology
Blood Parasite Screening and Identification (Haematology)
Haemosiderin Staining
Manual WBC Differential Count
Rapid Diagnostic Tests for Malaria (Haematology)
<b>Red Cell Enzymopathies</b>
G6PD Screen and Assay
Pyruvate Kinase Assay (Pilot)
<b>Educational</b>
Digital Blood Film Morphology for CPD*


Leucocyte Immunophenotyping	
<b>Tel:</b>	+44 (0) 114 267 3600
<b>Website:</b>	<a href="http://www.ukneqasli.co.uk">www.ukneqasli.co.uk</a>
<b>Email:</b>	<a href="mailto:admin@ukneqasli.co.uk">admin@ukneqasli.co.uk</a> 
<b>Legal Entity:</b>	Sheffield Teaching Hospitals NHS Foundation Trust
Services Available	
<b>Flow Cytometry</b>	
CD34+ Stem Cell Enumeration	
Cerebrospinal Fluid (CSF) Immunophenotyping (Pilot)	
Competency Assessment and Instrument Validation Panel for Immune Monitoring	
Haematological Malignancy Bone Marrow Aspirate Assessment (Pilot)	
Immune Monitoring	
Leukaemia Diagnostic Interpretation (Part 2)	
Leukaemia Immunophenotyping (Part 1)	
Low Level Leucocyte Enumeration	
Measurable Residual Disease for ALL by Flow Cytometry	
Measurable Residual Disease for AML by Flow Cytometry (Pilot)	
Measurable Residual Disease for CLL by Flow Cytometry (Pilot)	
Measurable Residual Disease for Plasma Cell Myeloma by Flow Cytometry (Pilot)	
Paroxysmal Nocturnal Haemoglobinuria	
<b>Molecular</b>	
Myeloid Gene Panels (Pilot)	
BCR::ABL1 and AML Translocation	
BCR::ABL1 Kinase Domain Variant (Mutation)	
BCR::ABL1 Major Quantification	
BCR::ABL1 Minor Quantification (Pilot)	
BRAF p.Val600Glu (V600E) Mutation Status for	

\* not included in the current scope of accreditation

# Haematology


Leucocyte Immunophenotyping	
Services Available	
<b>Molecular (cont.)</b>	
Lymphoid Gene Panels (Pilot)	
FLT3 Mutation Status	
IG/TCR Clonality Status	
JAK2 p.Val617Phe (V617F) Mutation Status	
KIT p.Asp816Val (D816V) Mutation Status for Mast Cell Disease	
Lymphoplasmacytic Lymphoma/ Waldenström Macroglobulinemia (Pilot)	
Measurable Residual Disease for AML by Molecular Methods (Pilot)	
Myeloproliferative Neoplasms Diagnostic Testing (Pilot)	
NPM1 Mutation Status	
Paediatric Acute Leukaemia Translocations	
Post-Stem Cell Transplant Chimerism Monitoring	

# Immunology

Histocompatibility & Immunogenetics	
<b>Tel:</b>	+44 (0) 144 3622 185
<b>Website:</b>	www.ukneqashandi.org.uk 
<b>Email:</b>	handi@ukneqas.org.uk
<b>Legal Entity:</b>	Velindre University NHS Trust
Services Available	
Crossmatching by Flow Cytometry	
Cytotoxic Crossmatching	
DNA HLA Typing at 1st Field Resolution	
DNA HLA Typing to 2nd or 3rd Field Resolution	
Educational Cross Match	
Educational Interpretive Clinical Scenarios	
Educational Scheme	
HFE Typing	
HLA Antibody Detection	

# Immunology

Histocompatibility & Immunogenetics	
Services Available (cont.)	
HLA Antibody Specificity Analysis	
HLA Genotyping for Coeliac and other HLA associated diseases	
HLA Phenotyping	
HLA-B*57:01 Typing for Drug Hypersensitivity	
HLA-B27 Testing	
HPA Antibody Detection/Specification	
HPA Genotyping	
Interpretative: HFE Genotype and Hereditary Haemochromatosis	
Interpretive HLA Genotype	
KIR Genotyping	

Immunology, Immunochemistry & Allergy (IIA)	
<b>Tel:</b>	+44 (0) 114 271 5715
<b>Website:</b>	www.immqas.org.uk 
<b>Email:</b>	immunology@ukneqas.org.uk
<b>Legal Entity:</b>	Sheffield Teaching Hospitals NHS Foundation Trust
Services Available	
Allergy and Immunodeficiency	
Allergen Component Testing	
Allergen Specific IgE	
Fungal & Related Antigens	
IgG Subclasses	
Specific Microbial Antibodies (Tetanus/HiB/ Pneumococcal antibodies)	
Total IgE	
Tryptase	
Autoimmunity	
Acetylcholine Receptor Antibodies	
ANCA/GBM Antibodies	
Antibodies to Nuclear and Related Antigens (ANA/DNA/ENA)	


\* not included in the current scope of accreditation

# Immunology

Immunology, Immunochemistry & Allergy (IIA)
Services Available
<b>Autoimmunity (cont.)</b>
Bullous Dermatitis Antibodies
Coeliac Disease Antibodies
Diabetic Markers
Ganglioside Antibodies
General Autoimmune Serology (CCP/RF/TPO/TRAB/AMA/LKM/SMA/GPC)
Interferon Gamma Release Assays (Mycobacterium tuberculosis) IGRA TB
Myelin Associated Glycoprotein IgM Antibodies (MAG)
Myositis Associated Antibodies
NMDAR Antibodies (Pilot)
Paraneoplastic Antibodies
Phospholipase A2 Receptor Antibodies (PLA2R)
Phospholipid Antibodies
SARS-CoV-2 Antibodies
<b>Digital</b>
Cryoproteins (Pilot)
Digital ANA (Pilot)
Interpretative EQA (iEQA)*
<b>Immunochemistry</b>
Alkaline Phosphatase (ALP) Isoenzymes
Alpha 1 Antitrypsin and Phenotype Identification
$\beta$ 2 Microglobulin
C1 Esterase Inhibitor and Functional Complement Assays
C-Reactive Protein (CRP)
CSF Haem Pigments
CSF IgG Oligoclonal Bands
CSF Proteins and Biochemistry
CSF $\beta$ 2 Transferrin/Beta Trace Protein
Interleukin-6 (IL-6)

Immunology, Immunochemistry & Allergy (IIA)
Services Available
<b>Immunochemistry (cont.)</b>
Point of Care CRP (Pilot)
Procalcitonin
Ultrasensitive C-Reactive Protein
<b>Oncology</b>
Monoclonal Protein Identification
Prostate Specific Antigen (Total and Free PSA)
Tumour Markers (CA125/CA199/CA153/NSE/CgA (Pilot))
Ultrasensitive PSA

## Medical Microbiology


Microbiology	
<b>Tel:</b>	+44 (0) 208 905 9890
<b>Website:</b>	www.ukneqasmicro.org.uk 
<b>Email:</b>	organiser@ukneqasmicro.org.uk
<b>Legal Entity:</b>	UK Health Security Agency
Services Available	
<b>Bacteriology</b>	
AAFB Microscopy	
Antimicrobial Susceptibility	
Carbapenemase Producing Organisms (CPO)*	
Clostridioides difficile (previously Clostridium difficile)	
Community Medicine	
Faecal Pathogens	
General Bacteriology	
General Bacteriology & Antimicrobial Susceptibility	

\* not included in the current scope of accreditation

# Medical Microbiology

Microbiology
Services Available
<b>Bacteriology (cont.)</b>
Genital Pathogens
MRSA Screening
Mycobacteria Culture
Syphilis Serology
Urinary Antigens
<b>Molecular</b>
C. Trachomatis and N. Gonorrhoeae
CMV DNA Quantification
EBV DNA Quantification
HBV DNA Quantification
Hepatitis C RNA Detection
HIV 1 RNA Quantification
Molecular Detection Mycobacteria
Molecular Detection of HPV
Molecular Detection of Respiratory Viruses
Molecular Detection of SARS-CoV-2
Molecular Detection of Viruses in CSF
Respiratory Point of Care
Viral Gastroenteritis (also suitable for antigen testing)
<b>Mycology</b>
Antifungal Susceptibility
Cryptococcal Antigen Detection
Fungal Biomarkers
Mycology
<b>Virology</b>
Anti-HBs Detection
Blood Borne Viruses
Blood Donor Screen
Diagnostic Serology: Hepatitis Screen
Hepatitis B Serology
Hepatitis C Serology

Microbiology
Services Available
<b>Virology (cont.)</b>
Hepatitis E Detection
HIV Point of Care
HIV Serology
Immunity Screen
Measles and Mumps IgG Serology
Parvovirus B19 and Rubella Serology
Respiratory Rapid: RSV
Rubella IgG Serology
SARS-CoV2 Point of Care

Parasitology	
<b>Tel:</b>	+44 (0) 203 9081 371
<b>Website:</b>	www.ukneqasmicro.org.uk/ parasitology
	
<b>Email:</b>	parasite@ukneqas.org.uk
<b>Legal Entity:</b>	UK Health Security Agency
Services Available	
<b>Blood Parasitology</b>	
Faecal Parasitology	
Malaria Rapid	
Molecular Detection of Faecal Parasites	
Molecular Diagnosis of Malaria	
Parasite Serology	
Teaching for Blood and Faecal Parasites	
Toxoplasma Serology	



# Point of Care Testing (POCT)

UK NEQAS monitors, supports and educates non-laboratory trained operators to improve the quality of diagnostic test performance and interpretation of results. We offer external quality assessment (EQA) for POCT in the following areas:

Services Available	Provided By
Activated Clotting Time (ACT)	UK NEQAS Blood Coagulation
B-Type Natriuretic Peptide (BNP)	UK NEQAS Cardiac Markers
Cardiac Troponin I	UK NEQAS Cardiac Markers
Cardiac Troponin T	UK NEQAS Cardiac Markers
CKMB	UK NEQAS Cardiac Markers
Clinical Chemistry	UK NEQAS Birmingham Quality
C-Reactive Protein (CRP)	UK NEQAS Immunology, Immunochemistry
Cryptococcal Antigen	UK NEQAS Microbiology
D-Dimer	UK NEQAS Blood Coagulation
D-Typing	UK NEQAS Blood Transfusion Laboratory Practice (BTLP)
Fungal Biomarkers	UK NEQAS Microbiology
Glycated Haemoglobins	UK NEQAS Birmingham Quality
Haemoglobin Only	UK NEQAS Haematology
HIV	UK NEQAS Microbiology
INR Testing (CoaguChek XS series, CoaguChek Pro II, Xprecia Stride, i-STAT, LumiraDx)	UK NEQAS Blood Coagulation
Malaria Rapid	UK NEQAS Parasitology
Molecular Detection of Respiratory Viruses	UK NEQAS Microbiology
Myoglobin	UK NEQAS Cardiac Markers
NT-pro BNP	UK NEQAS Cardiac Markers
Pregnancy Testing	UK NEQAS Edinburgh Peptide Hormones
Respiratory Rapid: RSV	UK NEQAS Microbiology
Thromboelastometry and Thromboelastography	UK NEQAS Blood Coagulation
Urinary Antigens	UK NEQAS Microbiology
Urine Dipsticks	UK NEQAS Birmingham Quality
Viral Gastroenteritis (also suitable for antigen testing)	UK NEQAS Microbiology

# Pre- and Post-Analytical Quality Monitoring Service (PrepQ)

The control of pre- and post-analytical errors in diagnostic testing is recognised as a major contributor to the improvement in laboratory quality. Although the cause of many errors may be outside the laboratory, they waste resources and impair effective patient care.

## The UK NEQAS response

UK NEQAS has developed a web-based pre- and post-analytical quality monitoring service (PrepQ), as an external comparison tool. This tool gives the laboratory the opportunity to collate and monitor the incidence of errors beyond the analytical phase against their peers.

## Registering to PrepQ

Registration to the PrepQ monitoring service is flexible. It can be done by department, discipline, laboratory, hospital, or network, depending upon the individual participant's service arrangements. Regular monitoring periods allow the laboratory to return data at a frequency convenient to them against as many of the key assurance indicators as they are able to collect.

## PrepQ is a web-based service

The PrepQ service is offered on a secure on-line basis through the UK NEQAS Results and Reports service. Participants submit the number of quality failures compared to the number of opportunities for failure in a given time period. Performance evaluation is reported using sigma metrics, allowing immediate benchmarking with the laboratory's peers.

## Pre- and post-analytical case scenarios

PrepQ includes scenarios in pre- and post-analytical monitoring up to 4 times a year. The scenarios reflect current concerns in laboratory errors that originate outside the analytical phase. The responses are requested

in the form of multiple-choice questions and brief free-text comments, and the results are reported with a short expert commentary that can be used within the laboratory for education and service development.

## Is PrepQ available in your area?

Yes. PrepQ is an international programme and is available to any participant in any UK NEQAS service.

PrepQ covers a wide range of disciplines, including Blood Sciences (Haematology, Clinical Chemistry, and Immunology), Microbiology and other specialised areas.

## Schedule of Exercises

PrepQ offers a regular schedule of exercises, with generous data submission windows and rapid feedback to laboratories.

The current schedule allows data submission and reports on a monthly basis. Participants are alerted by email to opening and close dates.

## Interested?

If you would like to know more about the PrepQ service, which is provided as a benefit of UK NEQAS membership, and how it could help your laboratory, please contact us on this email: [prepq@ukneqas.org.uk](mailto:prepq@ukneqas.org.uk) or call us on +44 (0) 114 2611 689.

# Participating Countries

UK NEQAS is the **world leading** provider of clinical laboratory External Quality Assessment (EQA)/ Proficiency Testing (PT) programmes. Below, and continued on page 19, is a list of countries currently participating in UK NEQAS EQA/PT.

<b>A</b>	Croatia	Guinea
Afganistan	Cuba	Guyana
Albania	Curacao	<b>H</b>
Algeria	Cyprus	Haiti
Angola	Czech Republic	Honduras
Argentina	<b>D</b>	Hong Kong
Armenia	Denmark	Hungary
Aruba	Dominican Republic	<b>I</b>
Australia	<b>E</b>	Iceland
Austria	Ecuador	India
Azerbaijan	Egypt	Indonesia
<b>B</b>	El Salvador	Iran
Bangladesh	Equatorial Guinea	Iraq
Barbados	Estonia	Ireland
Belgium	Ethiopia	Isle of Man
Benin	<b>F</b>	Israel
Bermuda	Falkland Islands	Italy
Bolivia	Faroe Islands	<b>J</b>
Bosnia and Herzegovina	Fiji	Jamaica
Botswana	Finland	Japan
Brazil	France	Jordan
Bulgaria	French Guiana	<b>K</b>
Burkina Faso	French Polynesia	Kazakhstan
<b>C</b>	<b>G</b>	Kenya
Cambodia	Gambia	Kingdom of Bahrain
Cameroon	Georgia	Kosovo
Canada	Germany	Kuwait
Central Africa Republic	Ghana	Kyrgyzstan
Chile	Gibraltar	<b>L</b>
China	Greece	Lao PDR
Colombia	Greenland	Latvia
Congo, Democratic Republic	Guadeloupe	Lebanon
Costa Rica	Guatemala	Lesotho
Cote d'Ivoire	Guernsey	Liberia

# Participating Countries

<b>L (continued)</b>	<b>O</b>	South Korea
Liechtenstein	Oman	Spain
Lithuania	<b>P</b>	Sri Lanka
Luxembourg	Pakistan	Sudan
<b>M</b>	Palestine	Suriname
Macau	Panama	Swaziland
Macedonia	Papua New Guinea	Sweden
Madagascar	Paraguay	Switzerland
Malawi	Peru	<b>T</b>
Malaysia	Philippines	Taiwan
Mali	Poland	Tajikistan
Malta	Portugal	Tanzania
Martinique	<b>Q</b>	Tchad
Mauritania	Qatar	Thailand
Mauritius	<b>R</b>	Togo
Mexico	Republic of Ireland	Tunisia
Monaco	Republic of Korea	Turkey
Mongolia	Republic of Macedonia	Turkmenistan
Montenegro	Republic of Moldova	<b>U</b>
Morocco	Reunion	Uganda
Mozambique	Romania	Ukraine
Myanmar	Rwanda	United Arab Emirates
<b>N</b>	<b>S</b>	United Kingdom
Namibia	Saudi Arabia	United States of America
Nepal	Scotland	Uruguay
Netherlands	Senegal	Uzbekistan
New Caledonia	Serbia	<b>V</b>
New Zealand	Sierra Leone	Venezuela
Nicaragua	Singapore	Vietnam
Niger	Sint Maarten	<b>W, X, Y, Z</b>
Nigeria	Slovak Republic	Yemen
Northern Ireland	Slovenia	Zambia
Norway	South Africa	Zimbabwe

# Programme Index

#	Page	A	Page
1st Trimester (Down's syndrome and Trisomies T13 and T18)	6	Antibodies to Nuclear and Related Antigens (ANA/DNA/ENA)	12
1st Trimester (Down's syndrome using dried blood spots) (Pilot)	6	Antibody Identification	10
2nd Trimester (Down's syndrome)	6	Antibody Screening	10
2nd Trimester (Neural tube defects)	6	Antifungal Assays	5
β2 Microglobulin	13	Antifungal Susceptibility	14
<b>A</b>	<b>Page</b>	Anti-HBs Detection	14
A <sub>1</sub> Typing	10	Antimicrobial Susceptibility	13
AAFB Microscopy	13	Antithrombin Antigen and Activity Assays	9
Abnormal Haemoglobins	11	<b>Assays</b>	<b>9</b>
Abnormal ultrasound	8	Ataxia, including Hereditary Spastic Paraplegia (HSP)	7
ABO & D Grouping	10	<b>Autoimmunity</b>	<b>12, 13</b>
ABO Titration	10	<b>Automated Counting &amp; Related</b>	<b>10, 11</b>
<b>ABO Titration (ABOT)</b>	<b>10</b>	Automated Differential Leucocyte Count	10
ACE	5	<b>B</b>	<b>Page</b>
Acetylcholine Receptor Antibodies	12	<b>Bacteriology</b>	<b>13, 14</b>
Activated Clotting Time (ACT) for: Hemochron series ACT+, ACT-LR; i – Stat1, i – Stat Alinity	10	BCR::ABL1 and AML Translocation Identification	11
Activated Clotting Time (ACT) (POCT)	14	BCR::ABL1 Kinase Domain Variant (Mutation) Status	11
Activated Partial Thromboplastin Time (APTT)	9	BCR::ABL1 Major Quantification	11
Activated Protein C Resistance Assay	9	BCR::ABL1 Minor Quantification (Pilot)	11
Acute and Chronic Kidney Disease (Creatinine, Cystatin C, eGFR and AKI)	5	Bile Acids	5
Acute Lymphoblastic Leukaemia (ALL)	7	<b>Birmingham Quality</b>	<b>5</b>
ADAMTS13 Assays	9	Blood Borne Viruses	14
AFP, CEA and hCG	6	<b>Blood Coagulation</b>	<b>9, 10</b>
Alimentary Tract Pathology (GIST)	4	Blood Component Quality Monitoring	10
Alkaline Phosphatase (ALP) Isoenzymes	13	Blood Donor Screen	14
Allergen Component Testing	12	Blood Films for Morphology	11
Allergen Specific IgE	12	Blood Parasite Screening and Identification (Haematology)	11
<b>Allergy and Immunodeficiency</b>	<b>12</b>	<b>Blood Parasitology</b>	<b>14</b>
Alpha 1 Antitrypsin and Phenotype Identification	13	<b>Blood Transfusion Laboratory Practice (BTLF)</b>	<b>10</b>
Aminoglycoside Induced deafness	8	Bone Marrow Trepine Biopsy (BMT)	4
ANCA/GBM Antibodies	12	BRAF p.Val600Glu (V600E) Mutation Status for Hairy Cell Leukaemia	11
Andrology: Semen Analysis (Sperm Motility, Concentration & Morphology)	15	BRCA testing for ovarian and prostate cancer - somatic	8
<b>Antenatal Antibody Titration (ANT) (Pilot)</b>	<b>10</b>		
Antibiotic Assays	5		

# Programme Index

<b>B</b>	<b>Page</b>	<b>C</b>	<b>Page</b>
BRCA testing for ovarian, breast, prostate and pancreatic cancer - germline	8	Chronic Lymphocytic Leukaemia (CLL) IGHV mutation status	7
BRCA testing in prostate cancer – cfDNA	8	Chronic Lymphocytic Leukaemia (CLL) <i>TP53</i> analysis	7
Breast cancer - <i>PIK3CA</i> testing	8	Classification and interpretation of germline SNVs and indels	9
Breast cancer - Tumour expression profiling	8	Classification of <i>BRCA1</i> , <i>BRCA2</i> and other <i>HRR</i> gene variants	8
Breast HER2 ISH (Interpretive and Technical)	5	Classification of germline SNVs and indels	9
Breast Pathology (HER2 IHC)	4	Classification of germline variants (SNVs and CNVs)	8
Breast Pathology (Hormonal Receptors ER & PR)	4	<b>Clinical Chemistry</b>	<b>5, 6, 16</b>
Breast Pathology (Hormonal Receptors ER only)	4	Clinical Genetics - Cardiovascular disorders	7
Breast Pathology (Low Expression HER2 IHC) (Pilot)	4	Clinical Genetics - Dysmorphology	7
B-Type Natriuretic Peptide (BNP)	6, 16	Clinical Genetics - Metabolic disorders	7
Bullous Dermatitis Antibodies	13	Clinical Genetics - Monogenic disorders	7
<b>C</b>	<b>Page</b>	Clinical Genetics - Oncogenetic disorders	7
C. Trachomatis and N. Gonorrhoeae	14	<b>Clinical Genetics &amp; Genetic Counselling</b>	<b>7</b>
C1 Esterase Inhibitor and Functional Complement Assays	13	Clostridioides difficile (previously Clostridium difficile)	13
Calcium disorders	7	CMV DNA Quantification	14
Carbapenemase Producing Organisms (CPO)*	13	Coeliac Disease Antibodies	13
Cardiac disorders	7	Colorectal cancer - core	8
<b>Cardiac Markers</b>	<b>6</b>	Colorectal cancer - MMR	8
<b>Cardiac Markers Schemes (Laboratory)</b>	<b>6</b>	Community Medicine	13
<b>Cardiac Markers Schemes (Point of Care)</b>	<b>6, 16</b>	Competency Assessment and Instrument Validation Panel for Immune Monitoring	11
Cardiac Troponin I, Cardiac Troponin T, CKMB, Myoglobin, NT-proBNP	6	C-Peptide	6
Carrier screening	8	C-Reactive Protein (CRP)	13, 16
CD34+ Stem Cell Enumeration	11	Crossmatching	10
<b>Cellular Pathology</b>	<b>4, 5</b>	Crossmatching by Flow Cytometry	12
<b>Cellular Pathology Technique</b>	<b>4</b>	Cryoproteins (Pilot)	13
Central Nervous System (CNS) tumours	8	Cryptococcal Antigen Detection	14, 16
Cerebrospinal Fluid (CSF) Immunophenotyping (Pilot)	11	CSF Haem Pigments	13
Charcot Marie Tooth disease and related sensory and motor neuropathies	7	CSF IgG Oligoclonal Bands	13
Cholangiocarcinoma	8	CSF Proteins and Biochemistry	13
Chromosome Instability syndromes	7	CSF $\beta$ 2 Transferrin/Beta Trace Protein	13
Chronic Lymphocytic Leukaemia (CLL)	7	Cystic fibrosis and <i>CFTR</i> -related disorders	7
		Cytopathology	4
		Cytotoxic Crossmatching	12

# Programme Index

D	Page	E	Page
D-Dimer	9, 16	Educational Cross Match	12
D-Dimer for: Triage, Cobas H232	10	Educational Interpretive Clinical Scenarios	12
Detection of Cells Coated with C3d	10	Educational Scheme	12
Detection of Cells Coated with IgG	10	Embryology: Embryo Morphology, Time Lapse Annotation	15
Developmental delay	7	Emicizumab Assays*	10
Diabetic Markers	13	Endometrial tumours	8
Diagnostic Cytopathology	4	Enhanced Liver Fibrosis (ELF) Score	6
Diagnostic Cytopathology Cell Block	4	Epilepsy disorders	7
Diagnostic Serology: Hepatitis Screen	14	Erythrocyte Sedimentation Rate	10
Differences in sex development	7	Erythropoietin	5
<b>Digital</b>	<b>13</b>	Exome trio sequencing - postnatal	9
Digital ANA (Pilot)	13	Exome trio sequencing - prenatal	9
Digital Blood Film Morphology for CPD *	11	<b>Extended Red Cell Phenotyping (ERP) (Pilot)</b>	<b>10</b>
Digital Diagnostic Ultrastructural Pathology (Pilot)	4	Eye disorders	7
Digital Interpretative Diagnostic Cytopathology	4	<b>F</b>	<b>Page</b>
Digital Interpretative Synovial Fluid Crystals (Pilot)	4	Factor II, V, VII VIII, IX, X, XI, XII Assays	9
<b>Digital Interpretive Web Based Schemes</b>	<b>4</b>	Factor VIII Inhibitor Assay*	10
Digital Pathology (Pilot)	4	Faecal Haemoglobin	5
<b>Direct Antiglobulin Testing (DAT)</b>	<b>10</b>	Faecal Markers	5
Direct Immunofluorescence (DIF)	4	Faecal Pancreatic Elastase	5
DNA Diagnostics for Haemoglobinopathies	11	Faecal Parasitology	14
DNA extraction from formalin-fixed paraffin embedded (FFPE) tissue	9	Faecal Pathogens	13
DNA extraction from fresh tissue	9	Familial colorectal cancer and polyposis	7
DNA extraction from saliva	9	Familial endocrine tumour predisposition disorders	7
DNA extraction from venous blood	9	Familial Hypercholesterolaemia	7
DNA HLA Typing at 1st Field Resolution	12	<b>Fetomaternal Haemorrhage (FMH)</b>	<b>10</b>
DNA HLA Typing to 2nd or 3rd Field Resolution	12	FIB-4 Score	6
DNA quantification	9	Fibrinogen Assay (Clauss/MultifibrinU)	9
DOAC Assays (Dabigatran, Rivaroxaban, Apixaban, Edoxaban)	9	FIX Treatment Monitoring*	10
D-Typing	16	<b>Flow Cytometry</b>	<b>11</b>
<b>E</b>	<b>Page</b>	FLT3 Mutation Status	12
EBV DNA Quantification	14	Fluids	5
<b>Edinburgh Peptide Hormones</b>	<b>6</b>	FMH Quantification	10
<b>Educational</b>	<b>10, 11</b>	FMH Screening	10
		Fragile X syndrome and <i>FMRI-related disorders</i>	7
		Frozen Section (Companion Scheme to Specialist Techniques and Neuropathology)	4

# Programme Index

<b>F</b>	<b>Page</b>	<b>H</b>	<b>Page</b>
Fructosamine	5	Haematological Technical FISH	7
FSH, LH, AMH, Prolactin and Growth Hormone	6	<b>Haematology</b>	<b>9, 10, 11, 12</b>
Full Blood Count	10	Haemoglobin only	11, 16
Fungal & Related Antigens	12	<b>Haemoglobinopathies and Thalassaemia</b>	<b>11</b>
Fungal Biomarkers	14, 16	Haemosiderin Staining	11
FVIII Treatment Monitoring	10	HBV DNA Quantification	14
FXIII Assays	9	<b>Head &amp; Neck Pathology</b>	<b>4</b>
<b>G</b>	<b>Page</b>	Head and Neck Pathology (Oral, ENT & Combined)*	4
G6PD Screen and Assay	11	Heparin Assay (HA) - Anti-Xa	9
Ganglioside Antibodies	13	Heparin Dosage Assessment (HDA) by APT	9
Gastric HER2 IHC	4	Hepatitis B Serology	14
Gastrin	6	Hepatitis C RNA Detection	14
Gastrohepatology disorders	7	Hepatitis C Serology	14
Gastrointestinal Stromal Tumours (GIST)	8	Hepatitis E Detection	14
General Autoimmune Serology (CCP/RF/TPO/TRAB/AMA/LKM/SMA/GPC)	13	Hereditary breast and ovarian cancer disorders (HBOC)	7
General Bacteriology	13	HFE Typing	12
General Bacteriology & Antimicrobial Susceptibility	13	High Sensitivity Cardiac Troponin I (Pilot)	6
General Pathology	4	High-risk HPV in Head & Neck Pathology (Pilot)	5
Genetic counselling	7	<b>Histocompatibility &amp; Immunogenetics</b>	<b>12</b>
Genetics of Heritable Bleeding and Thrombotic Disorders	10	HIT Screening/Assays*	10
Genital Pathogens	14	HIV 1 RNA Quantification	14
<b>Genomic and Inherited Disorders</b>	<b>7</b>	HIV Point of Care	14, 16
Genomic laboratory training videos	8	HIV Serology	14
Genomic multi-disciplinary team (MDT) working	7	HLA Antibody Detection	12
<b>Genomics</b>	<b>7, 8, 9</b>	HLA Antibody Specificity Analysis	12
Genotyping and Predicted Red Cell Phenotype for Various Blood Groups	10	HLA Genotyping for Coeliac and other HLA associated diseases	12
<b>GenQA</b>	<b>7, 8, 9</b>	HLA Phenotyping	12
Glycated Haemoglobins	5, 16	HLA-B*57:01 Typing for Drug Hypersensitivity	12
<b>Guildford Peptide Hormones &amp; Trace Elements</b>	<b>6</b>	HLA-B27 Testing	12
<b>H</b>	<b>Page</b>	Holo-transcobalamin	5
Haematinics	5	Homocysteine Assays	9
Haematological Malignancy Bone	11	HPA Antibody Detection/Specification	12
<b>Haematological Neoplasms</b>	<b>7</b>	HPA Genotyping	12

# Programme Index

H	Page	J	Page
hs Cardiac Troponin I, hs Cardiac Troponin T, CKMB, Myoglobin, NT-proBNP	6	JAK2 p.Val617Phe (V617F) Mutation Status	12
Huntington disease and DRPLA	7	K	Page
Hyaluronic acid	6	Ki-67 in Breast Cancer (Pilot)	5
Hypotonic Infant	7	KIR Genotyping	12
I	Page	KIT p.Asp816Val (D816V) Mutation Status for Mast Cell Disease	12
IG/TCR Clonality Status	12	L	Page
IgG Subclasses	12	Lead, Cadmium, Manganese, Arsenic, Magnesium*, Mercury, Zinc*, Selenium, Thallium, Chromium and Cobalt in Whole Blood	6
Immune Monitoring	11	<b>Leucocyte Immunophenotyping</b>	<b>11, 12</b>
Immunity Screen	14	Leukaemia Diagnostic Interpretation (Part 2)	11
<b>Immunochemistry</b>	<b>13</b>	Leukaemia Immunophenotyping (Part 1)	11
<b>Immunocytochemistry</b>	<b>4</b>	Linkage analysis	7
<b>Immunocytochemistry &amp; In-Situ Hybridisation</b>	<b>4</b>	Lipid Investigations	5
<b>Immunology</b>	<b>12, 13</b>	Liquid Newborn Haemoglobinopathy Screening	11
<b>Immunology, Immunochemistry &amp; Allergy (IIA)</b>	<b>12, 13</b>	<b>Liver Fibrosis Markers</b>	<b>6</b>
Immunosuppressants	5	Low Level Leucocyte Enumeration	11
Imprinting disorders	7	Lung cancer - Circulating free (cf) DNA in lung cancer	8
Inborn errors of metabolism	7	Lung cancer – comprehensive molecular	8
<b>Individual Competency Assessment</b>	<b>8</b>	Lung cancer - EGFR	8
Infectious Mononucleosis	11	Lung cancer – fusions FISH/IHC	8
Infertility	7	Lung cancer – fusions molecular	8
INR for: CoaguChek XS, CoaguChek XS Plus, CoaguChek XS Pro & Pro II, Xprecia Stride, istat, LumiraDx	10, 16	Lupus Anticoagulant Screening/Assay	9
<b>In-Situ Hybridisation</b>	<b>5</b>	Lymphoid Gene Panels (Pilot)	12
Insulin	6	Lymphoid Pathology	4
Insulin-like Growth Factor 1	6	Lymphoma	7
Insulin-like Growth Factor Binding Protein-3	6	Lymphoma Technical NGS	7
Interferon Gamma Release Assays (Mycobacterium tuberculosis) IGRA TB	13	Lymphoplasmacytic Lymphoma/Waldenström Macroglobulinemia (Pilot)	12
Interleukin-6 (IL-6)	13	M	Page
Interpretative Comments in Clinical Chemistry	5	Malaria Rapid	14, 16
Interpretative EQA (iEQA) *	13	Manual WBC Differential Count	11
Interpretative: HFE Genotype and Hereditary Haemochromatosis	12	Maternal cell contamination (MCC) and fetal sexing	8
Interpretive HLA Genotype	12	<b>Maternal Serum Screening</b>	<b>6</b>
Intrinsic Factor Antibodies	5	Measles and Mumps IgG Serology	14
ISCN	9		

# Programme Index

M	Page	M	Page
Measurable Residual Disease for ALL by Flow Cytometry	11	Molecular testing for Severe Combined Immunodeficiency (SCID)	8
Measurable Residual Disease for AML by Flow Cytometry (Pilot)	11	Molecular testing for Spinal Muscular Atrophy (SMA)	8
Measurable Residual Disease for AML by Molecular Methods (Pilot)	12	Molecular Tissue identification	8
Measurable Residual Disease for CLL by Flow Cytometry (Pilot)	11	Monitoring (TDM)	5
Measurable Residual Disease for Plasma Cell Myeloma by Flow Cytometry (Pilot)	11	Monoclonal Protein Identification	13
<b>Medical Microbiology</b>	<b>13, 14</b>	<b>Morphology Related</b>	<b>11</b>
Mega Block (Companion Scheme to Specialist Techniques and Neuropathology)	4	MRSA Screening	14
Melanoma	8	Muscle Histochemistry	4
Mercury, Cadmium, Copper, Iron, Zinc, Chromium, Cobalt, Arsenic, Lead, Manganese, Nickel, Thallium and Selenium in Urine	6	Muscular dystrophies	7
<b>Microbiology</b>	<b>13, 14</b>	Mycobacteria Culture	14
Microdeletion syndromes	7	<b>Mycology</b>	<b>14</b>
Microsatellite Instability (MSI)	8	Myelin Associated Glycoprotein IgM Antibodies (MAG)	13
Mismatch Repair (MMR) Proteins	4	Myeloid disorders	7
Mitochondrial disease	7	Myeloid Gene Panels (Pilot)	11
Mohs' Procedure	4	Myeloma	7
<b>Molecular</b>	<b>11, 12, 14</b>	Myeloproliferative Neoplasms Diagnostic Testing (Pilot)	12
Molecular Detection Mycobacteria	14	Myositis Associated Antibodies	13
Molecular Detection of Faecal Parasites	14	<b>N</b>	<b>Page</b>
Molecular Detection of HPV	14	Neurodegenerative disorders	7
Molecular Detection of Respiratory Viruses	14, 16	Neurofibromatosis and rasopathies	7
Molecular Detection of SARS-CoV-2	14	Neuropathology	4
Molecular Detection of Viruses in CSF	14	Newborn Screening	5
Molecular Diagnosis of Malaria	14	Newborn Sickle Screening	11
Molecular Genetics of Thrombophilia Testing (Factor V Leiden)	10	Next Generation Sequencing (NGS) for germline CNVs	9
<b>Molecular Newborn Screening</b>	<b>8</b>	Next Generation Sequencing (NGS) for germline SNVs and indels	9
<b>Molecular Pathology</b>	<b>8</b>	Next Generation Sequencing (NGS) for somatic SNVs and indels - tumour testing only	9
Molecular testing for cystic fibrosis (CF)	8	Next Generation Sequencing (NGS) for somatic SNVs and indels - tumour with germline subtraction analysis	9
Molecular testing for Medium-chain acyl-CoA dehydrogenase deficiency (MCADD)	8	NMDAR Antibodies (Pilot)	13
		Non-invasive prenatal testing (NIPT) for common aneuploidies	8
		Non-invasive prenatal testing (NIPT) for common microdeletions	8

# Programme Index

<b>N</b>	<b>Page</b>	<b>P</b>	<b>Page</b>
Non-invasive prenatal testing (NIPT) for fetal RhD status	8	<b>Peptide II</b>	<b>6</b>
Non-invasive prenatal testing (NIPT) for fetal sexing	8	PGT for aneuploidies (PGT-A)	8
Non-Small Cell Lung Cancer (NSCLC) ALK IHC	4	PGT for blastomere FISH	8
Non-Small Cell Lung Cancer (NSCLC) ALK ISH (Pilot)	5	PGT for monogenic disorders	8
Non-Small Cell Lung Cancer (NSCLC) PD-L1 IHC (Pilot)	4	PGT for structural rearrangements (PGT-SR)	8
Non-Small Cell Lung Cancer (NSCLC) ROS1 FISH (Pilot)	5	<b>Pharmacogenomics</b>	<b>8</b>
Non-Small Cell Lung Cancer (NSCLC) ROS1 IHC (Pilot)	5	Pharmacogenomics panel	8
NPM1 Mutation Status	12	Phospholipase A2 Receptor Antibodies (PLA2R)	13
NTRK fusions	8	Phospholipid Antibodies	13
<b>O</b>	<b>Page</b>	Placental Growth Factor (PLGF)	6
<b>Oncology</b>	<b>13</b>	Plasma Metanephrines	5
Optical Genome Mapping	9	Plasma Viscosity	11
<b>Other Programmes</b>	<b>9, 10</b>	Plasminogen Assay	9
<b>P</b>	<b>Page</b>	POCT Haematology (Pilot)	11
p16 in Head & Neck Pathology (Pilot)	5	Point of Care CRP (Pilot)	13
Paediatric Acute Leukaemia Translocations	12	<b>Point of Care D Typing (POCTD)</b>	<b>10</b>
Paediatric Bilirubin	5	<b>Point of Care Testing (POCT)</b>	<b>10, 16</b>
Paraneoplastic Antibodies	13	Postnatal constitutional copy number variants (CNV) detection	7
Parasite Serology	14	Postnatal karyotyping	7
<b>Parasitology</b>	<b>14</b>	Post-Stem Cell Transplant Chimerism Monitoring	12
Paroxysmal Nocturnal Haemoglobinuria	11	Pre- and Post-Analytical Quality (PrepQ)	17
Participating Countries	18, 19	Prediction of Clopidogrel effectiveness (CYP2C19)	8
Parvovirus B19 and Rubella Serology	14	Prediction of Fluorouracil toxicity (DPYD)	8
Pathogenicity of germline postnatal copy number variants (CNV)	9	Prediction of Thiopurine toxicity (TPMT & NUDT15)	8
Pathogenicity of haematological neoplasm variants	9	<b>Pre-eclampsia Markers</b>	<b>6</b>
Pathogenicity of prenatal copy number variants (CNV)	9	Pregnancy loss	8
Pathogenicity of RNA splicing variants	9	<b>Pregnancy Testing</b>	<b>6, 16</b>
Pathogenicity of somatic sequence variants	9	<b>Preimplantation Genetic Testing (PGT)</b>	<b>8</b>
<b>Peptide I</b>	<b>6</b>	Prenatal constitutional copy number variant (CNV) detection	8
		Prenatal karyotyping	8
		<b>Pre-Transfusion Testing (PTT)</b>	<b>10</b>
		Primary Immunodeficiency disorders (PID)	7
		Procalcitonin	13

# Programme Index

<b>P</b>	<b>Page</b>	<b>S</b>	<b>Page</b>
Prostate Specific Antigen (Total and Free PSA)	13	<b>Screening Tests</b>	<b>9</b>
Protein C Antigen and Activity Assay	9	Serum Indices (HIL)	5
Protein S Activity Assay	9	SFlt-1	6
Protein S Total and Free Antigen Assay	9	SFlt-1: PLGF ratio	6
Prothrombin Time (PT)/INR (Venous/ Capillary Methods)	9	Sickle Screening only	11
Prothrombin Time for Diagnosis (PT/ Diagnostic) (PTD)	9	Skeletal Dysplasias	7
PTH, ACTH and Calcitonin	6	<b>Slide Based Schemes</b>	<b>4</b>
Pyruvate Kinase Assay (Pilot)	11	Specialist Techniques	4
		Specific Microbial Antibodies (Tetanus/ HiB/Pneumococcal antibodies)	12
<b>Q</b>	<b>Page</b>	Specific Proteins	5
Quantitative Amino Acids	5	Steroid Hormones	5
		Sweat Testing	5
<b>R</b>	<b>Page</b>	Syphilis Serology	14
Rapid Diagnostic Tests for Malaria (Haematology)	11		
Rapid prenatal testing for common aneuploidies	9	<b>T</b>	<b>Page</b>
Red Cell Antibody Titration	10	Teaching for Blood and Faecal Parasites	14
<b>Red Cell Enzymopathies</b>	<b>11</b>	<b>Technical</b>	<b>9</b>
<b>Red Cell Genotyping (RCG) (Pilot)</b>	<b>10</b>	Thrombin Time (TT)	9
Renal Biopsy Pathology	4	Thromboelastography for: TEG & TEG6	10, 16
Renal disorders	7	Thromboelastometry for: Rotem Delta, Rotem Sigma	10, 16
Renal tumours	8	Thyroglobulin	5
<b>Reproductive Genetics</b>	<b>8, 9</b>	Thyroid cancer	8
<b>Reproductive Science</b>	<b>15</b>	Thyroid Hormones	5
Respiratory disorders	7	Tissue assessment	8
Respiratory Point of Care	14	Tissue Diagnostics	4
Respiratory Rapid: RSV	14, 16	Tissue inhibitor of metalloproteinase I (TIMP-I)	6
Reticulocyte Count	11	Total IgE	12
Reticulocyte Haemoglobin Content (Pilot)	11	Toxicology (TOX) and Therapeutic Drug	5
Rh and K Phenotyping	10	Toxoplasma Serology	14
RhD Typing	10	Training, Assessment and Competency Tool (TACT)	10
Rubella IgG Serology	14	Transmission Electron Microscopy (TEM)	4
		Triple Negative Breast Cancer (TNBC) PD-L1 IHC (Pilot)	5
<b>S</b>	<b>Page</b>	Tryptase	12
<b>Sample Handling</b>	<b>9</b>	<b>Tumour Markers</b>	<b>6</b>
Sarcoma	8	Tumour Markers (CA125/CA199/CA153/ NSE/CgA (Pilot)	13
SARS-CoV-2 Antibodies	13		
SARS-CoV2 Point of Care	14		

# Programme Index

<b>T</b>	<b>Page</b>
Type III Procollagen Peptide (PIIINP)	6
<b>U</b>	<b>Page</b>
Ultrasensitive C-Reactive Protein	13
Ultrasensitive PSA	13
Urinary Antigens	14, 16
Urinary Catecholamines & Metabolites	5
Urinary hCG (Qualitative and Quantitative)	6
Urine Chemistries	5
Urine Dipsticks	5, 16
<b>V</b>	<b>Page</b>
<b>Variant Classification &amp; Interpretation</b>	<b>9</b>
Variant validation	9
Various Blood Group Antigen Phenotyping	10
Viral Gastroenteritis (also suitable for antigen testing)	14, 16
<b>Virology</b>	<b>14</b>
Vitamin Assays (Carotene, Vitamin A & E)	5
Vitamin D	5
Vitamin K	5
Von Willebrand Factor Antigen: Assay	9
VWF:CB (Collagen-Binding) Assay	9
VWF:RCo (Activity) Assay	9
<b>W, X, Y, Z</b>	<b>Page</b>
<b>Web Based Schemes</b>	<b>4</b>
X-inactivation	7
Zinc, Copper, Aluminium, Selenium, Chromium and Cobalt in Serum	6

# UK NEQAS Centre Contacts

UK NEQAS Centre	Telephone Number	Email Address
Birmingham Quality	+44 (0) 121 414 7300	birminghamquality@uhb.nhs.uk
Blood Coagulation	+44 (0) 114 267 3300	neqas@coageqa.org.uk
Blood Transfusion Laboratory Practice (BTLP)	+44 (0) 192 358 7111	btlp@ukneqas.org.uk
Cardiac Markers	+44 (0) 141 440 2888	info@ukneqas-cm.org.uk
Cellular Pathology Technique	+44 (0) 191 816 1030	cpt@ukneqas.org.uk
Edinburgh Peptide Hormones	+44 (0) 131 242 6885	ukneqas@ed.ac.uk
GenQA	+44 (0) 131 242 6898	info@genqa.org
Guildford Peptide Hormones & Trace Elements	+44 (0) 148 357 1122 ext. 3611	rsch.peptideeqa@nhs.net rsc-tr.Guildford-EQA@nhs.net
Haematology	+44 (0) 192 358 7111	haem@ukneqas.org.uk
Head & Neck Pathology	+44 (0) 121 371 5723	neckpath@ukneqas.org.uk
Histocompatibility & Immunogenetics	+44 (0) 144 362 2185	handi@ukneqas.org.uk
Immunocytochemistry & In-Situ Hybridisation (ICC&ISH)	+44 (0) 208 187 9174	info@ukneqasiccish.org
Immunology, Immunochemistry & Allergy (IIA)	+44 (0) 114 271 5715	immunology@ukneqas.org.uk
Leucocyte Immunophenotyping (LI)	+44 (0) 114 267 3600	admin@ukneqasli.co.uk
Microbiology	+44 (0) 208 905 9890	organiser@ukneqasmicro.org.uk
Parasitology	+44 (0) 203 908 1371	parasite@ukneqas.org.uk
Reproductive Science	+44 (0) 161 276 6437	repscience@ukneqas.org.uk

## General Enquiries

### UK NEQAS Central Office

PO Box 401  
Sheffield  
South Yorkshire  
S5 7YZ.

T: +44 (0) 114 261 1689  
E: [centraloffice@ukneqas.org](mailto:centraloffice@ukneqas.org)  
W: [www.ukneqas.org.uk](http://www.ukneqas.org.uk)